Lupin Limited (Lupin) and Aptissen S.A. (Aptissen) announced that they have entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in Canada. This includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis. Based on Statistics Canada, Osteoarthritis affects more than 10% of Canadians aged 15 or older.

Synolis VA (Visco-Antalgic) is the intra-articular injection product for osteoarthritis with a unique combination of Hyaluronic Acid and high concentration of Sorbitol. Synolis VA 40/80 is already approved by Health Canada and an additional strength is currently under review.

Commenting on this development, Dr. Sofia Mumtaz, President of Lupin Pharma Canada stated, “We are pleased to partner with Aptissen for marketing and distribution of Synolis VA, a branded product in Canada. This partnership helps us expand our product portfolio in the Canadian market. We remain committed to bring superior medical products and leverage our distribution strength to allow easy access to specialty medicines in the market.”

Aptissen S.A. is a Swiss company founded in 2013 as a spin-off of ANTEIS and is based in the Geneva area, Switzerland.  Aptissen revolutionized the market by launching Synolis VA, the first intra-articular injection which combines Hyaluronic Acid (HA) with antioxidant (Sorbitol).